SCHEMBL6409284

SCHEMBL6409284

CC(C)(C)OC(=O)C1c2ccccc2N[C@@H]1COc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.41
EGFR P00533 3/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.33
ATM Q13315 1/20 0.33
ABCB1 P08183 1/20 0.33
RECQL P46063 1/20 0.33
MAPK10 P53779 1/20 0.33
ALOX15 P16050 2/20 0.33
PPARA Q07869 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
GFER P55789 1/20 0.33
MAPK1 P28482 1/20 0.32
EPHX2 P34913 1/20 0.32
ALPL P05186 1/20 0.32
ALPI P09923 1/20 0.32
ALPG P10696 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7369050 0.68 EGFR (0.42) IDO1EGFRKMT2AMEN1ATM
SCHEMBL11192210 0.68 IDO1 (0.41) IDO1KMT2AGAAEPHX2
SCHEMBL11192189 0.68 IDO1 (0.41) IDO1KMT2AGAAEPHX2
SCHEMBL10101481 0.68 MME (0.39) PPARA
SCHEMBL691998 0.65 MAPT (0.55) IDO1KMT2AMEN1MAPK10GAA
SCHEMBL14719041 0.65 KLK7 (0.40) IDO1KMT2AMEN1ATMABCB1
SCHEMBL2448079 0.63 ALOX15 (0.57) KMT2AMEN1ALOX15MAPTALPL
SCHEMBL29221974 0.63 EGFR (0.43) IDO1EGFRKMT2AMEN1ALOX15
SCHEMBL22988664 0.63 EPHX2 (0.44) IDO1EGFRKMT2AABCB1MAPK10
SCHEMBL19095322 0.63 EPHX2 (0.44) IDO1EGFRKMT2AABCB1MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050250798-A1 E.g., 8-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]sulfonyl}-3,4-dihydropyrimido[1,2-a]indol-10(2H)-one; caspase inhibitors used to treat diseases including arthritis, myocardial infarction or stroke WYETH (US) 2005-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250798-A1 E.g., 8-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]sulfonyl}-3,4-dihydropyrimido[1,2-a]indol-10(2H)-one; caspase inhibitors used to treat diseases including arthritis, myocardial infarction or stroke CASP1, API5, CASP8 IDO1 28/4885EGFR 3729/4885KMT2A 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.